Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
A. Menzies-Gow (London, United Kingdom), J. Corren (Los Angeles, United States of America), E. Israel (Boston, United States of America), T. Welte (Hannover, Germany), C. Ambrose (Gaithersburg, United States of America), B. Cook (Gaithersburg, United States of America), G. Hunter (Cambridge, United Kingdom), J. Llanos-Ackert (Thousand Oaks, United States of America), G. Colice (Gaithersburg, United States of America). Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR. 876

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The prevelance of chronic nasal symptoms in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 264s Year: 2002 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020 Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018